🇺🇸 FDA
Patent

US 8080532

Compositions and methods for inhibiting expression of Huntingtin gene

granted A61PA61P25/00A61P25/14

Quick answer

US patent 8080532 (Compositions and methods for inhibiting expression of Huntingtin gene) held by Alnylam Pharmaceuticals, Inc. expires Mon Dec 15 2031 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Alnylam Pharmaceuticals, Inc.
Grant date
Tue Dec 20 2011 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 15 2031 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
24
CPC classes
A61P, A61P25/00, A61P25/14